construction-preclinical-multimodality-phantom-using-tissue-mimicking

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement

World Health Organization (WHO) and the Response Evaluation Criteria in Solid Tumors (RECIST) working groups advocated standardized criteria for ...

University of Kansas School of Medicine

University of Texas Health Science Center at San Antonio

There are growing expectations that imaging biomarkers for tumor therapeutic drug response assessment will speed up preclinical testing of anticancer drugs in rodent models. The only imaging biomarker presently approved by the U.S. Food and Drug Administration is tumor size measurement based on either World Health Organization (WHO) criteria or Response Evaluation Criteria in Solid Tumors (RECIST). Frequently, preclinical data are accumulated from multiple research centers on multiple continents using scanners from different manufacturers and sometimes even using different imaging modalities. Very expensive cancer drug response studies can be compromised by inadequate controls to assure precision and accuracy of tumor size measurements. This project was undertaken to develop standardized quality assurance (QA) procedures using a multimodality preclinical tumor response phantom to validate the accuracy of tumor size measurements based on WHO criteria, RECIST, or global tumor volume criteria for evaluation of cytostatic drugs.

QA procedures for multimodality preclinical tumor drug response testing.

Il y a des attentes croissantes que biomarqueurs pour &eacute;valuation de r&eacute;ponse th&eacute;rapeutique pharmacologique tumeur d&#39;imagerie permettra d&#39;acc&eacute;l&eacute;rer les tests pr&eacute;cliniques de m&eacute;dicaments anticanc&eacute;reux dans les mod&egrave;les de rongeurs. Les biomarqueurs d&#39;imagerie seule actuellement approuv&eacute; par la Food and Drug Administration est bas&eacute;e sur les crit&egrave;res de l&#39;Organisation mondiale de la sant&eacute; (OMS) ou Response Evaluation Criteria in Solid Tumors (RECIST) mesure la taille tumorale. Fr&eacute;quemment, les donn&eacute;es pr&eacute;cliniques sont accumul&eacute;es par plusieurs centres de recherche sur plusieurs continents &agrave; l&#39;aide de scanners de diff&eacute;rents fabricants et parfois m&ecirc;me en utilisant diff&eacute;rentes modalit&eacute;s d&#39;imagerie. Tr&egrave;s chers m&eacute;dicaments r&eacute;ponse &eacute;tudes sur le cancer peuvent &ecirc;tre compromises par le manque de contr&ocirc;les ad&eacute;quats pour assurer la pr&eacute;cision et l&#39;exactitude des mesures de taille de tumeur. Ce projet a &eacute;t&eacute; entrepris pour d&eacute;velopper des proc&eacute;dures d&#39;assurance (QA) de qualit&eacute; standardis&eacute;e utilisant une multimodalit&eacute; fant&ocirc;me pour valider l&#39;exactitude des mesures de taille de tumeur de la r&eacute;ponse tumorale pr&eacute;cliniques bas&eacute;e sur les crit&egrave;res de l&#39;OMS, RECIST ou crit&egrave;res de volume tumoral global d&#39;&eacute;valuation des m&eacute;dicaments cytostatiques.

Proc&eacute;dures AQ pour multimodalit&eacute; tumeur pr&eacute;clinique drogue test de r&eacute;ponse.

Ci sono delle aspettative crescenti che imaging biomarkers per la valutazione di risposta terapeutica del farmaco tumore accelerer&agrave; test preclinici di farmaci antitumorali nei modelli di roditori. L&#39;unico biomarcatore imaging attualmente approvato dalla US Food and Drug Administration &egrave; tumore dimensione misura basata su criteri di organizzazione mondiale della sanit&agrave; (OMS) o criteri di valutazione della risposta nei tumori solidi (RECIST). Frequentemente, dati preclinici sono accumulati da diversi centri di ricerca su pi&ugrave; continenti utilizzando scanner da diversi produttori e a volte anche diverse modalit&agrave; di imaging. Studi di cancro molto costoso farmaco risposta possono essere compromessa da controlli inadeguati per assicurare la precisione e l&#39;accuratezza delle misurazioni di dimensioni del tumore. Questo progetto &egrave; stato intrapreso per sviluppare procedure di garanzia (QA) qualit&agrave; standardizzata utilizzando un multimodalit&agrave; risposta tumore preclinico fantasma per validare l&#39;accuratezza delle misurazioni dimensioni tumore basato su criteri WHO, RECIST o criteri di volume tumorale globale per la valutazione dei farmaci citostatici.

Procedure QA per multimodalit&agrave; tumore preclinico droga test risposta.

Valutazione della variazione delle dimensioni del tumore dalle immagini acquisite da ultrasuoni (US), la tomografia computerizzata (TC) o risonanza magnetica (MRI) &egrave; una misura comune di efficacia di chemioterapia del cancro. Tumore dimensione misura in base ai criteri dell&#39;organizzazione mondiale della sanit&agrave; (OMS) o i criteri di valutazione della risposta nei tumori solidi (RECIST) &egrave; l&#39;unico biomarcatore imaging per il farmaco anti-cancro test attualmente approvati per la United States Food and Drug Administration (FDA). Lo scopo di questa carta &egrave; stata di progettare e testare un fantasma di garanzia della qualit&agrave; con la capacit&agrave; di monitoraggio di modifiche delle dimensioni del tumore con pi&ugrave; preclinical imaging scanner (US, CT e MRI) al fine di facilitare il test preclinico anticancerogeno.

Design fantasma multimodalit&agrave; preclinica per garantire la qualit&agrave; di misura di dimensione del tumore.

Evaluation of changes in tumor size from images acquired by ultrasound (US), computed tomography (CT) or magnetic resonance imaging (MRI) is a common measure of cancer chemotherapy efficacy. Tumor size measurement based on either the World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid Tumors (RECIST) is the only imaging biomarker for anti-cancer drug testing presently approved by the United States Food and Drug Administration (FDA). The aim of this paper was to design and test a quality assurance phantom with the capability of monitoring tumor size changes with multiple preclinical imaging scanners (US, CT and MRI) in order to facilitate preclinical anti-cancer drug testing.

Preclinical multimodality phantom design for quality assurance of tumor size measurement.

&Eacute;valuation des changements dans la taille de la tumeur d&#39;images obtenues par &eacute;chographie (US), la tomodensitom&eacute;trie (TDM) ou l&#39;imagerie par r&eacute;sonance magn&eacute;tique (IRM) est une commune mesure de l&#39;efficacit&eacute; de chimioth&eacute;rapie du cancer. Mesurage de la taille tumorale bas&eacute;e sur les crit&egrave;res de l&#39;Organisation mondiale de la sant&eacute; (OMS) ou le Response Evaluation Criteria in Solid Tumors (RECIST) est le seul biomarqueur d&#39;imagerie pour le d&eacute;pistage des drogues anticanc&eacute;reuses actuellement approuv&eacute;es par l&#39;United States Food et pharmaceutiques (FDA). Le but de cet article a &eacute;t&eacute; de concevoir et de tester un fant&ocirc;me d&#39;assurance de la qualit&eacute; avec la capacit&eacute; de surveillance des changements de taille de tumeur avec plusieurs scanners d&#39;imagerie pr&eacute;cliniques (US, CT et IRM) afin de faciliter le d&eacute;pistage des drogues anticanc&eacute;reuses pr&eacute;clinique.

Conception fant&ocirc;me de multimodalit&eacute; pr&eacute;clinique pour l&#39;assurance de la qualit&eacute; du mesurage de la taille tumorale.

Definitive radiation therapy for locally advanced cervical cancer involves external beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy. There remains controversy and practice pattern variation regarding the optimal radiation dose to metastatic pelvic lymph nodes (LNs). This study investigates the contribution of the pelvic LN dose from HDR brachytherapy.

The equivalent dose contribution from high-dose-rate brachytherapy to positive pelvic lymph nodes in locally advanced cervical cancer.

D&eacute;finitif de radioth&eacute;rapie pour le cancer du col ut&eacute;rin localement avanc&eacute; consiste &agrave; radioth&eacute;rapie externe (radioth&eacute;rapie externe) et la curieth&eacute;rapie haut d&eacute;bit de dose (HDR). Il reste encore la variation de la controverse et la pratique concernant la dose de rayonnement optimal &agrave; m&eacute;tastatiques des ganglions pelviennes (LNs). Cette &eacute;tude examine la contribution de la dose de LN pelvienne de curieth&eacute;rapie.

La contribution de dose &eacute;quivalente de curieth&eacute;rapie haut-d&eacute;bit de dose &agrave; ganglionnaire pelvien dans le cancer du col ut&eacute;rin localement avanc&eacute;.

Yongsook C. Lee

Department of Radiation Oncology

University of Kansas School of Medicine

Construction of a Preclinical Multimodality Phantom Using Tissue-mimicking Materials for Quality Assurance in Tumor Size Measurement